MDT
Medtronic plc$89.89
Unclear
Target $91.71
Report: Mar 11, 2026Healthcare • Medical - Devices • Mature CompounderSnapshot
Decision-first overview with recommendation, valuation anchor, and current setup.
Company Overview
Research Snapshot
Price History
Pelican View
Current$89.89+2.0%
Rec: UnclearConviction: High
Entry Target
$70.55
(22% below current)
Fair Value
$91.71
(2% above current)
Stop Loss
$68.84
(23% below current)
Position Size
Half
Time Horizon
Long-Term (3+ Years)
Key Metrics
Live Snapshot
Market Data
52 Week High$106.33
52 Week Low$79.55
Avg. 3 Month Volume8.39M
Efficiency
LTM Gross Margin64.9%
LTM EBITDA Margin26.3%
LTM EBIT Margin17.6%
LTM Operating Margin17.0%
LTM ROA5.0%
LTM ROE9.5%
LTM ROIC11.4%
LTM ROCE7.8%
Capital Structure
Market Cap (MM)$111.2B
Enterprise Value (MM)$138.2B
Shares Outstanding1.28B
Total Debt (MM)$28.07B
Cash & Equivalents (MM)$1.15B
LTM Net Debt (MM)$26.92B
LTM Net Debt/EBITDA2.9x
Growth
TTM Rev. Growth6.9%
Last 3-Yr Rev. CAGR4.9%
Last 3-Yr EBITDA CAGR2.4%
Last 3-Yr EPS CAGR5.7%
Valuation
Street Target Price$111.45
LTM EV/Revenue3.9x
LTM EV/Gross Profit6.0x
LTM EV/EBIT22.1x
LTM EV/EBITDA14.8x
LTM P/E24.1x
LTM EV/FCF25.5x
LTM P/FCF20.6x
LTM P/TB2.8x
LTM P/B2.3x
Dividend Yield2.4%
Payout Ratio58.9%
Executive SummarySituation: Current price is $89.89 versus fair value $91.71 (2.0% expected return), and valuation confidence is stable. Debate: Bull case depends on Diabetes Business Spin-off: The separation of the lower-margin Diabetes unit is expected to be immediately accretive to corporate margins and allow for a more focused valuation multiple. Bear case centers on Moat Erosion in Robotics: The primary risk is that Intuitive Surgical's dominant network effect and technological lead in robotics permanently impair Medtronic's ability to gain share with the Hugo system, leading to lower-than-expected... Conclusion: Recommendation is Unclear; maintain no position until reliability and catalyst evidence improve.
Bull Case
The Diabetes spin-off and Elliott-led operational improvements will unlock significant margin expansion; The PFA and RDN platforms are entering a high-growth phase with broad CMS coverage; 151% cash conversion provides ample capital for both the 3.1% dividend yield and tuck-in M&A.
Bear Case
Persistent margin compression from capital-intensive product mix and tariffs ($185M headwind) may prove structural; Competitive pressure from Intuitive Surgical in robotics could limit Hugo's market share; High leverage (59.4% Debt/Equity) and rising interest rates increase financial risk.
Key Catalysts
Mid-Term (6-18 months)Impact: High
Diabetes Business Spin-off: The separation of the lower-margin Diabetes unit is expected to be immediately accretive to corporate margins an...
Near-Term (0-6 months)Impact: Critical
Hugo RAS System U.S. Rollout: The successful commercial launch and first clinical cases of the Hugo robotic system in the U.S. will validate...
Long-Term (18+ months)Impact: Moderate
Medtronic is at a critical juncture as it integrates activist-led governance changes and prepares for its largest structural change in a dec...
Primary Risks
Concern: Medium
Moat Erosion in Robotics: The primary risk is that Intuitive Surgical's dominant network effect and technological lead in robotics permanent...
Concern: High
Tariff and Geopolitical Exposure: Persistent or escalating trade tensions, particularly with China, could lead to structural margin compress...
Concern: Medium
The governance outlook is defined by the following Outcome Tree: 1. Status Quo: Management executes the current plan, leading to 5.5% organi...
Recent Activity
2025-02-15SEC Filing (SC 13G/A)
-7.26%Medtronic and Covidien Group file Schedule 13G/A reporting 15.4% beneficial ownership of Orchestra BioMed shares.
2024-05-23SEC Filing (8-K)
-5.11%Medtronic reports FY24 and Q4 financial results with 3.6% revenue growth and 47th consecutive dividend increase
2022-11-22SEC Filing (8-K)
-5.30%Medtronic reports Q2 FY2023 financial results; revenue declined 3% as reported but increased 2% organic.
2022-05-26SEC Filing (8-K)
-5.78%Medtronic reports FY22 and Q4 financial results with 5% revenue growth and 8% dividend increase
2021-12-15SEC Filing (8-K)
-6.04%Medtronic enters Third Amendment to Amended and Restated Credit Agreement, extending maturity to December 2026.
Valuation Table
9.8/10Decision Grade
Scenario Range
$64
Bear
$92
Base
$110
Bull
$90